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A Ab bs st tr ra ac ct t
Catechol-O-methyltransferase (COMT) is vital for the conjugation of catechol estrogens that are produced
during oestrogen metabolism. The efficiency of this process varies due to a polymorphism in COMT, which
changes valine to methionine (V158M). The Met genotypes slow the metabolism of catechol oestrogens,
which are agents that are capable of causing DNA damage through the formation of DNA adducts and
reactive oxygen species (ROS) production. The slower metabolism of catechol oestrogens results in there
being a higher circulating concentration of these oeastrogens and consequently greater probability of DNA
damage. To determine whether metabolic inefficiencies of oeastrogen metabolism are associated with the
development of malignancy in hereditary non-polyposis colorectal cancer (HNPCC), we studied the V158M
polymorphism in COMT in a large cohort of 498 HNPCC patients from Australia and Poland that were
either mutation positive (n=331) or negative (n=167) for mismatch repair (MMR) gene mutations (hMLH1
or hMSH2). HNPCC is a familial predisposition to colorectal cancer (CRC) and extracolonic cancers that
include endometrial cancer.
Using Real Time PCR, the COMT V158M polymorphism was examined and its association with disease
expression, age of diagnosis of cancer, mutation status and mutation type was assessed in the HNPCC
MMR mutation positive and negative groups. This study showed that the V158M polymorphism had no
association with disease risk in the HNPCC MMR mutation positive population. However, the polymorphism
was significantly associated with endometrial/ovarian cancer risk in HNPCC MMR mutation negative patients
(p=0.002). The heterozygous (Val/Met) genotype was associated with an increased risk of developing
endometrial/ovarian cancer whereas the homozygous mutant (Met/Met) showed a decreased risk. The
results suggest heterosis, where there is an apparent greater effect of the heterozygous state in this
dichotomous trait. In conclusion, this study shows that the COMT V158M polymorphism alters the risk of
developing endometrial/ovarian cancer in patients that adhere to the Amsterdam HNPCC criteria but do
not have a DNA mismatch repair gene mutation.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2006; 4(2) 95
I In nt tr ro od du uc ct ti io on n
Hereditary non-polyposis colorectal cancer
(HNPCC) is an autosomal dominant inherited disorder
associated with a familial predisposition to colorectal
cancer (CRC) and endometrial cancer (EC). It is
characterised by early age of disease (CRC) onset,
neoplastic lesions, microsatellite instability (MSI) and
an increased incidence of extracolonic cancers [1].
Familial colorectal cancer syndromes, HNPCC and
familial adenomatous polyposis (FAP), account for
around 3% of all colorectal cancer cases; however,
approximately 20% show familial inheritance of which
there is no known genetic cause [2]. Mutations of the
genes involved in the mismatch repair pathway, hMLH1
and hMSH2, account for a large proportion of patients
that fit the HNPCC clinical criteria [1, 3].
Approximately 80% of men and 40% of women that
have germline mutations in MMR genes develop CRC
[1, 4] and 25-50% and 8-12% of women develop
endometrial cancer and ovarian cancer, respectively
[5]. While environmental factors are thought to play
an important role in HNPCC disease aetiology, other
as yet unknown genetic factors are also likely to
contribute to HNPCC disease susceptibility, and it has
been suggested that single nucleotide polymorphisms
(SNPs) contribute to disease. Polymorphisms in genes
involved in many biological pathways (DNA repair,
xenobiotic clearance, immune response and a number
of other pathways) have been examined, but the role
of polymorphisms in oestrogen metabolism genes has
not been characterised in the HNPCC population.
Catechol-O-methyltransferase (COMT) is a phase
II enzyme involved in oestrogen metabolism. It catalyses
the addition of a methyl group to catechol oestrogens
and converts them into methoxy derivatives [6]. Catechol
oestrogens are believed to contribute to oestrogen-in-
duced cancer through their ability to initiate DNA
damage by the formation of DNA adducts and reactive
oxygen species (ROS) [7, 8]. 2-Methoxyestrone has
a protective role in the development of cancer since it is
antioestrogenic, inhibits tumour growth, stimulates
apoptosis and inhibits angiogenesis [6-9]. Therefore, the
conversion of catechol oestrogen into 2-methoxyestrone
is important in the elimination of toxic agents by
conjugation [10]. The highest COMT activity occurs within
the brain, liver, kidney, endometrium and breast [11].
The first study examining the function of COMT
revealed that its activity is low, intermediate or high [12].
The three levels of activity correspond to a trimodal
distribution. In 1995, Lotta et al. [13] identified a G to
A polymorphism in COMT, which results in a valine to
methionine amino acid change at position 158 of the
gene (known as V158M). COMT is polymorphic within
the general population since approximately 50% have
the intermediate and 25% have the low activity forms
of the polymorphism [14]. The A allele is thought to be
associated with a 4-5 times less efficient metabolism of
oestradiol than the G allele [12], which subsequently
allows the accumulation of higher circulating levels of
oestradiol. Heterozygous individuals have intermediate
COMT activity [14].
The V158M polymorphism has been studied in
a variety of hormonally influenced cancers such as
prostate [15], breast [16 and references within], ovarian
[17, 18] and endometrial cancer [19, 20]. Some of
these studies have found positive associations between
the low activity allele and cancer risk but other studies
have not found any association and in some cases the
opposite association has been reported. For that
reason, the role of V158M polymorphism in COMT
and cancer risk remains unresolved. 
To our knowledge there have been no studies
examining the COMT V158M polymorphism and
colorectal and endometrial cancer risk in HNPCC
patients. So far, there have been only two studies that
have looked at the V158M polymorphism and
endometrial cancer and three studies involving
colorectal cancer. A study by Doherty et al. [19] showed
a modest decreased risk of developing endometrial
cancer with the Met allele, which was not expected.
Another study by McGrath et al. [20] found no
association between endometrial cancer and the
polymorphism. In addition, a study by Sasaki et al. [21]
showed that promoter region of membrane bound
COMT (MB-COMT) was methylated in 47/60
endometrial cancer tumours. Methylation of the
promoter region silences the gene and they concluded
that this may contribute to endometrial carcinogenesis.
All of the studies that examined the polymorphism and
colorectal cancer susceptibility showed no associations
[22-24]. Also, Garner et al. [17] and Sellers et al. [18]
studied ovarian cancer susceptibility and the COMT
V158M polymorphism. Garner et al. [17] concluded
that Val/Met variant of COMT decreases the risk for
mucinous tumours, but both studies reported no other
associations. In conclusion, the role of the V158M
polymorphism in COMT and its relation to cancer have
previously shown inconsistent findings.
Since endometrial cancer is the most common
cancer in women that have HNPCC and the genetics
of endometrial and ovarian cancer within the context
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of HNPCC are poorly understood, it is important to
identify other genes involved in susceptibility to disease.
COMT is a good candidate as another gene involved
in disease since COMT is highly expressed within the
endometrium and previous studies have shown
associations between the COMT polymorphism and
oestrogen-influenced cancers. Additionally, the
functioning of COMT is important for the degradation
of catechol oestrogen and the conversion to 2-metho-
xyestrone to prevent the formation of DNA adducts and
ROS. For this reason, the role of the V158M polymor-
phism in COMT is important to elucidate in the
HNPCC population.
M Ma at te er ri ia al ls s   a an nd d   m me et th ho od ds s
S Su ub bj je ec ct ts s
498 patients were included in this study. The
patients were selected from across the state of New
South Wales and from Poland because they fulfilled the
clinical criteria of hereditary non-polyposis colorectal
cancer (HNPCC). Approval for this study was obtained
from the Hunter Area Research Ethics Committee
(Australia), the University of Newcastle Human Research
Ethics Committee (Australia) and the Ethics Committee
of the Pomeranian Academy of Medicine (Poland). All
patients enrolled in this study had given informed
consent for their anonymous DNA to be used for
research into genetic predispositions to colorectal
cancer. Two HNPCC groups were examined: those with
mutations in MMR genes, hMLH1 or hMSH2 (mutation
positive – 331 patients) and those without mutations
in these genes (mutation negative – 167 patients).
H HN NP PC CC C  M MM MR R  M Mu ut ta at ti io on n  P Po os si it ti iv ve e  P Po op pu ul la at ti io on n
The selection criteria for the HNPCC MMR mutation
positive group were based on the molecular diagnosis
of HNPCC; 331 patients harboured a confirmed
causative mutation in either hMLH1 or hMSH2, of
which there were 285 nonsense, insertion, deletion or
splice mutations (leading to a truncated protein) and 46
missense mutations described as pathogenic in the
International Society for Gastrointestinal Hereditary
Tumours (InSiGHT) mutation database. There were two
subpopulations of Caucasians in this study – Australian
and Polish. In the Australian population, there were 197
samples collected in the state of New South Wales
from 1998 to 2004, and in the Polish population there
were 134 samples collected from 1997 to 2002. Of
the 331 individuals, 149 had been diagnosed with
colorectal cancer: 94 in the Australian population
and 55 in the Polish population. Of the 197 Australian
and 134 Polish patients, 107 (54%) and 78 (58%) were
relatives of probands, respectively. 
P Po op pu ul la at ti io on n  s su ub bg gr ro ou up ps s
To determine any association between the disease
characteristics of the mutation positive group and the
V158M polymorphism, the samples were subdivided
into different subgroups according to: (i) gene mutation
status (hMLH1 or hMSH2); (ii) mutation type:
truncation/deletion (including insertion, deletion,
nonsense and splice site changes) or pathogenic
missense mutations and; (iii) disease expression
(affected/unaffected with CRC or affected/unaffected
with endometrial/ovarian cancer). The age of onset of
CRC was defined as the patient’s age at diagnosis,
while the age of the unaffected patients was determined
by subtracting their date of birth from their age at the
time of testing. A subgroup of patients unaffected with
CRC over the age of 45 years was prepared to
compare with the patients affected with CRC. This was
performed since patients under the age of 45 years
whom are not affected with disease could possibly still
develop disease later in life. The age of diagnosis of
CRC was unknown for 7 Australian and 5 Polish
patients, and the disease expression status was
unknown for 4 Australian patients.
C Co om mb bi in ne ed d  H HN NP PC CC C  m mu ut ta at ti io on n  p po os si it ti iv ve e  p po op pu ul la at ti io on ns s  
( (A Au us st tr ra al li ia an n  a an nd d  P Po ol li is sh h) )
The Australian and Polish populations were
combined to determine any association between the
disease characteristics of the mutation positive group
and the V158M polymorphism. The analysis was
performed in the same way as mentioned above
(population subgroups).
H HN NP PC CC C  M Mu ut ta at ti io on n  N Ne eg ga at ti iv ve e  P Po op pu ul la at ti io on n
To determine if the V158M polymorphism is
associated with disease expression in HNPCC mutation
negative patients, the samples were divided into those
affected with CRC and affected or unaffected with
endometrial/ovarian cancer. The mutation negative
population was previously tested to determine whether
they harboured a germline mutation in the hMLH1 or
hMSH2 genes by denaturing high performance liquid
chromatography (dHPLC) analysis followed by direct
sequencing, multiplex ligation probe amplification
(MLPA) assay and denaturing gradient gel electropho-
resis (DGGE). From all analyses performed, noH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2006; 4(2) 97
mutation was found in the samples. This group of
patients was collected from 1997 to 2004. Within this
group there were 167 Australian samples, all of which
were affected with CRC or affected/unaffected with
endometrial/ovarian cancer (155 affected with
CRC, 21 affected with endometrial/ovarian cancer, 9
affected with both CRC and endometrial/ovarian
cancer). Of the 167 patients, 6 (3.5%) were relatives
or probands. The age of diagnosis of CRC was
unknown for 2 patients.
D DN NA A  i is so ol la at ti io on n
Genomic DNA was isolated from Na2EDTA blood
according to the method previously described by Miller
et al. [25].
R Re ea al l- -t ti im me e  P PC CR R  S SN NP P  g ge en no ot ty yp pi in ng g
DNA samples were genotyped to determine the allele
frequency of the COMT V158M polymorphism. Allelic
discrimination was performed on an ABI PRISM 7900HT
sequencing detection system (PE Applied Biosystems,
Foster City). Assay-by-Design
SM, a service offered by
Applied Biosystems (PE Applied Biosystems), was used to
design primers and probes. The primers and probes used
were 5”-CCCAGCGGATGGTGGAT-3” (forward
primer), 5”-CAGGCATGCACACCTTGTC-3” (reverse
primer), 5”-VIC-TTCGCTGGCATGAAG-3” (wildtype
probe) and 5”-FAM-TCGCTGGCGTGAAG-3” (mutant
probe). The assay functions under universal conditions
with each reaction containing: 50 ng DNA, 0.125 μl 40×
Assay Mix and 2.5 μl TaqMan Universal PCR master mix
made up to 5 μl with sterile water. The thermal cycling
conditions were 50°C for 2 min, 95°C for 10 min,
and 70 cycles of 92°C for 15 sec and 60°C for 1 min.
Post PCR, the plate was scanned to allow discrimination
between the different genotypes.
S St ta at ti is st ti ic ca al l  a an na al ly ys si is s
Statistical analysis was undertaken to assess whether
or not the polymorphism segregates with specific types
of disease expression, mutation type, mutation status
or age of diagnosis of CRC in HNPCC patients. The
Hardy-Weinberg equilibrium (HWE) was assessed for
the subject groups. All statistical tests were performed
on the statistical software package Intercooled
Stata 8.0 (Stata Corporation, Texas) and Statistical
Package for the Social Sciences (SPSS) 12.0 (SPSS,
Chicago). The significance levels for all tests were set
at p<0.05. The genotype distribution between the
different groups was analysed using Pearson’s
chi-squared test and if the number of samples in
a given group was less than 5, Fisher’s exact test was
used. Kaplan-Meier survival analysis was used to
compare genotype and age of diagnosis of CRC. To
assess the homogeneity of the survival curves the
Wilcoxon, log rank and Tarone-Ware tests were used.
The log rank p value was only reported when there
were no significant results.
R Re es su ul lt ts s
H HN NP PC CC C  M Mu ut ta at ti io on n  P Po os si it ti iv ve e  G Gr ro ou up p
D Di is se ea as se e   e ex xp pr re es ss si io on n   i in n   A Au us st tr ra al li ia an n   H HN NP PC CC C   m mu ut ta at ti io on n
p po os si it ti iv ve e   p pa at ti ie en nt ts s   c co om mp pa ar re ed d   t to o   P Po ol li is sh h   p pa at ti ie en nt ts s
There was no significant difference in the frequency
of affected and unaffected CRC patients observed
between the two populations. The proportion of hMLH1
and hMSH2 carriers was similar in both populations,
and the proportion of colorectal cancer patients was
similar for hMLH1 and hMSH2 mutation carriers. The
subgroup endometrial/ovarian cancer had a similar
frequency of individuals affected and unaffected with
CRC (11 affected and 12 unaffected in Australia and 5
affected and 9 unaffected in Poland). In addition there
was no significant difference between the two
populations in the frequency of truncation/deletion and
missense mutations.
A Al ll le el le e   f fr re eq qu ue en nc cy y   d di is st tr ri ib bu ut ti io on n   o of f   C CO OM MT T   V V1 15 58 8M M   i in n
A Au us st tr ra al li ia an n   a an nd d   P Po ol li is sh h   H HN NP PC CC C   m mu ut ta at ti io on n   p po os si it ti iv ve e   p pa at ti ie en nt ts s   
The distribution of the V158M polymorphism in
this study was in Hardy-Weinberg equilibrium (HWE)
in both populations. The three genotypes in the
V158M polymorphism were Val/Val (homozygous
wildtype/GG), Val/Met (heterozygous/GA) and
Met/Met (homozygous mutant/AA). There was
a statistically significant difference in the allele
frequency distribution of the polymorphism between
the two populations (p=0.02). The Australian
population had a higher frequency of the
heterozygous genotype and a lower frequency of the
homozygous mutant genotype compared to the
Polish population. When the subject group was
subdivided according to their gene mutation status
there was a significant difference observed between
the Australian and Polish hMLH1 mutation carriers
(p=0.03), where the Australian patients had a much
higher proportion of the Val/Met (GA) genotype and
a much lower proportion of the Met/Met (AA)
genotype. There was no statistical difference seen
between the Australian and Polish hMSH2 mutation
carriers. There was a statistically significant result
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involving the patients unaffected with CRC between
the two populations (p=0.02). The Australian
population had a higher frequency of the
heterozygous genotype and a lower frequency of the
homozygous mutant genotype in comparison to the
Polish population (see Table 1).
A Al ll le el le e   f fr re eq qu ue en nc cy y   d di is st tr ri ib bu ut ti io on n   i in n   t th he e   A Au us st tr ra al li ia an n   a an nd d
P Po ol li is sh h   g gr ro ou up ps s   a an na al ly ys se ed d   s se ep pa ar ra at te el ly y   a an nd d   c co om mb bi in ne ed d
When assessing disease expression, mutation status
and mutation type between the different subgroups in
the two populations separately, there were no significant
difference observed in the Australian and Polish
populations. In addition there were no significant
differences involving disease expression, mutation status
and mutation type when the populations were
combined (see Table 2).
M Me ed di ia an n   a ag ge e   o of f   d di ia ag gn no os si is s   o of f   C CR RC C   i in n   t th he e   s su ub bj je ec ct t   g gr ro ou up ps s
The median age of diagnosis of CRC was similar
in both populations, 42.5 years in the Australian group
with a range from 17 to 70 years and 44 years in the
Polish group with a range from 18 to 78 years. In
individuals with hMLH1 and hMSH2 mutations the
median age of diagnosis was 42 years for both in the
Australia population, with a range from 17 to 64 years
in hMLH1 mutation carriers and 22-76 years in hMSH2
mutation carriers. In the Polish population the median
age of diagnosis was 45 years for hMLH1 mutation
carriers (32-78 years) and 41 years for hMSH2
mutation carriers (18-78 years).
K Ka ap pl la an n- -M Me ei ie er r   s su ur rv vi iv va al l   a an na al ly ys si is s
There was no significant difference between
genotype and age of diagnosis of CRC in the
T Ta ab bl le e 1 1. .   Allele frequency distribution of the COMT V158M polymorphism in the Australian and Polish HNPCC MMR mutation positive patients
G Gr ro ou up p P Po op pu ul la at ti io on n V Va al l/ /V Va al l   ( (% %) ) V Va al l/ /M Me et t   ( (% %) ) M Me et t/ /M Me et t   ( (% %) ) n n P Pe ea ar rs so on n’ ’s s   
C Ch hi i- -s sq qu ua ar re ed d
subject group Australia 53 (26.9) 108 (54.8) 36 (18.3) 197 p=0.02
Poland 33 (24.6) 59 (44.0) 42 (31.3) 134
hMLH1 mutation carriers Australia 31 (28.7) 59 (54.6) 18 (16.7) 108 p=0.03
Poland 17 (23.0) 32 (43.2) 25 (33.8) 74
hMSH2 mutation carriers Australia 22 (24.7) 49 (55.1) 18 (20.2) 89 p=0.41
Poland 16 (26.7) 27 (45.0) 17 (28.3) 60
mutation type: truncation/deletion Australia 50 (28.2) 95 (53.7) 32 (18.1) 177 p=0.05
Poland 26 (24.1) 49 (45.4) 33 (30.6) 108
mutation type: missense Australia 3 (15.0) 13 (65.0) 4 (20.0) 20 p=0.20
Poland 7 (26.9) 10 (38.5) 9 (30.6) 26
affected with CRC Australia 24 (25.5) 51 (54.3) 19 (20.2) 94 p=0.88
Poland 14 (25.5) 28 (50.9) 13 (23.6) 55
unaffected with CRC Australia 28 (28.3) 53 (53.5) 18 (18.2) 99 p=0.02
Poland 19 (24.1) 31 (39.2) 29 (36.7) 79
unaffected with CRC (>45 years) Australia 10 (23.3) 24 (55.8) 9 (20.9) 43 P=0.84
Poland 5 (22.7) 11 (50) 6 (27.2) 22
endometrial/ovarian cancer Australia 6 (26.1) 14 (60.9) 3 (13.0) 23 p=0.12
Poland 5 (35.7) 4 (28.6) 5 (35.7) 14
affected with CRC and unaffected  Australia 22 (22.7) 57 (58.8) 18 (18.6) 97 p=0.09
with endometrial/ovarian cancer Poland* 28 (23.3) 55 (45.8)  37 (30.8) 120
* This group contained males and females. The sex was unknown for all of the patients.
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T Ta ab bl le e 2 2. .   Allele frequency distribution of the COMT V158M polymorphism in the Australian and Polish HNPCC MMR mutation positive
patients combined
G Gr ro ou up p V Va al l/ /V Va al l   ( (% %) ) V Va al l/ /M Me et t   ( (% %) ) M Me et t/ /M Me et t   ( (% %) ) n n P Pe ea ar rs so on n’ ’s s   
C Ch hi i- -s sq qu ua ar re ed d
subject group 86 (26.0) 167 (50.5) 78 (23.6) 331
hMLH1 mutation carriers 48 (26.4) 91 (50.0) 43 (23.6) 182
p=0.98
hMSH2 mutation carriers 38 (25.5) 76 (51.0) 35 (23.5) 149
mutation type: truncation/deletion 76 (26.7) 144 (50.5) 65 (22.8) 285
p=0.65
mutation type: missense 10 (21.7) 23 (50.0) 13 (28.3) 46
affected with CRC 38 (25.5) 79 (53.0) 32 (21.5) 149
p=0.50
unaffected with CRC 47 (26.4) 84 (47.2) 47 (26.4) 178
unaffected with CRC (>45 years) 15 (23.1) 35 (53.8) 15 (23.1) 65 p=0.92**
endometrial/ovarian cancer 11 (29.7) 18 (48.6) 8 (21.6) 37
p=0.66
affected with CRC and unaffected with endometrial/ovarian cancer* 50 (23.0) 112 (51.6) 55 (25.3) 217
* This group contained males and females. The sex was unknown for all of the patients.
** This group was compared to patients affected with CRC
Australian and Polish groups (Australian population
p=0.19 and Polish population p=0.48). However,
there was a trend observed in the Australian
population where patients with the Met/Met genotype
had a later age of onset of CRC compared to the
other genotypes.
H HN NP PC CC C  M Mu ut ta at ti io on n  N Ne eg ga at ti iv ve e  G Gr ro ou up p
D Di is se ea as se e   e ex xp pr re es ss si io on n   i in n   A Au us st tr ra al li ia an n   H HN NP PC CC C   m mu ut ta at ti io on n
n ne eg ga at ti iv ve e   p pa at ti ie en nt ts s
The distribution of the V158M polymorphism was
in Hardy-Weinberg equilibrium (HWE) in this
population. There was a statistically significant
difference in genotype frequency between patients
affected with endometrial/ovarian cancer compared
to those unaffected (p=0.002) (see Table 3). The
endometrial/ovarian cancer group had a higher
frequency of the heterozygous (GA) genotype and
lower frequency of the other genotypes in comparison
to the patients unaffected with endometrial/ovarian
cancer (see Fig. 1). 
M Me ed di ia an n   a ag ge e   o of f   d di ia ag gn no os si is s   o of f   C CR RC C
The median age of diagnosis of CRC in the
HNPCC MMR mutation negative group was 51 years
with a range of 19 to 74 compared to 42.5 years with
a range of 17 to 70 years in the mutation positive
Australian group. The 8.5 years difference in median
age was not statistically significant. 
K Ka ap pl la an n- -M Me ei ie er r   s su ur rv vi iv va al l   a an na al ly ys si is s
There was no significant difference between
genotype and age of diagnosis of CRC in the
Australian mutation negative group (p=0.81).
F Fi ig g. . 1 1. .   Allele frequency distribution of the COMT V158M polymorphism
in the Australian HNPCC MMR mutation negative patients assessed
by endometrial/ovarian cancer disease expression
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D Di is sc cu us ss si io on n
There have been numerous candidate SNP studies
performed in the past involving colorectal cancer and
endometrial cancer, which have focused on a variety of
biological pathways. The role of modifier genes in disease
is becoming recognised as an important factor in
understanding the variation that can be observed in
individuals who harbour mutations in the same gene. In
addition they could possibly account for a proportion of
patients that do not harbour a mutation in a known gene,
yet still fit the clinical characteristics of the syndrome.
In this study, we examined the V158M polymorphism
in COMT to determine its association with colorectal
cancer and endometrial/ovarian cancer in two different
groups: an Australian and a Polish population that
harboured a mutation in hMLH1 or hMSH2, and an
Australian population that did not harbour a mutation
in hMLH1 or hMSH2. COMT is involved in oestrogen
metabolism and it functions to methylate catechol
derivatives to render these carcinogens inactive [6].
Functional studies performed demonstrate that the Met
allele hinders the metabolism of oestradiol and allows
for greater levels of oestradiol to circulate [12]. One
recent study showed that the Met allele has the same
level of activity as the Val allele but has greater
susceptibility to 4-hydroxyequilenin (4-OHEN) mediated
inhibition and thermolability [26].
The frequency of the three genotypes Val/Val,
Val/Met and Met/Met in the subject groups
were 26.9%, 54.8% and 18.3% Australian MMR
mutation positive, 24.6%, 44%, 31.3% Polish MMR
mutation positive, and 27.0%, 46.7% and 26.3% in the
Australian MMR mutation negative genotype
frequencies. The Polish and Australian MMR mutation
negative frequencies are in accordance with a number
of Caucasian control groups [18, 27-29] and provide
evidence that there is no difference in the allele
frequencies between HNPCC patients in our study and
other Caucasian populations. However, the genotype
frequency in the Australian MMR mutation positive group
was statistically significantly different to the Polish
population in addition to the other control populations.
This is most likely due to the high numbers of relatives
involved in the study.
The significant differences observed in the mutation
positive group when the Australian population was
compared to the Polish population (gene mutation
status, hMLH1 p=0.03 and disease expression,
unaffected with CRC p=0.02) can be accounted for
by the fact that this population is not random and
contains a large proportion of proband relatives. When
the Australian and Polish MMR mutation positive
populations were either compared separately or as
a combined group there were no significant differences
in the frequency of the COMT polymorphism, which
suggests that the V158M variant does not influence
disease expression, gene mutation status, mutation type
or age of diagnosis of CRC.
In the mutation negative group, a statistically
significant difference was observed in relation to
endometrial/ovarian cancer (p=0.002). Patients
affected with endometrial/ovarian cancer had a higher
frequency of the Val/Met genotype and a lower
frequency of the other genotypes in comparison to those
patients unaffected with endometrial/ovarian cancer.
The samples used for this part of the study were from
the Australian population only; therefore we believe the
results to be representative of mutation negative HNPCC
families from Australia, and it remains to be seen if these
results are similar in other populations.
The significance of these results can be interpreted
in two different ways. Firstly, the Val/Met genotype is
known to cause intermediate activity of COMT and
consequently it is less efficient in the detoxification of
the oestrogen metabolites within the endometrium,
which ultimately leads to carcinogenesis. Secondly, the
low frequency of the Met/Met genotype in the
endometrial/ovarian cancer group indicates
a protective role of this genotype. The results suggest
that endometrial/ovarian cancer susceptibility is more
complex than the COMT V158M polymorphism and
it is indicative that many other genes or other variants
T Ta ab bl le e 3 3. .   Allele frequency distribution of the COMT V158M polymorphism in the Australian HNPCC MMR mutation negative patients
G Gr ro ou up p V Va al l/ /V Va al l   ( (% %) ) V Va al l/ /M Me et t   ( (% %) ) M Me et t/ /M Me et t   ( (% %) ) n n P Pe ea ar rs so on n’ ’s s   
C Ch hi i- -s sq qu ua ar re ed d
subject group 45 (26.9) 78 (46.7) 44 (26.4) 167
endometrial/ovarian cancer 3 (14.3) 16 (76.2) 2 (9.5) 21
p=0.002
affected with CRC and unaffected with endometrial/ovarian cancer* 35 (30.4) 41 (35.7) 39 (33.9) 115
* This group contained females only.
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within COMT will provide further insight into the
mechanisms of disease in HNPCC. Li et al. [26]
reported that the Ala22Ser polymorphism in COMT
showed lower methylation capacity and higher
thermolability and thus might be of functional
importance in oestrogen-related cancers. These results
are of interest since there has previously been no
known genetic predisposition in patients that fit the
clinical criteria for HNPCC who do not have a MMR
gene mutation. COMT V158M therefore could
account for some of the endometrial/ovarian cancer
cases within the HNPCC population. Alternatively, this
may be an example of heterosis [see review 30], where
there is an apparent greater effect of the heterozygous
state in this dichotomous trait.
Other studies performed involving the COMT
V158M polymorphism and CRC, endometrial cancer
and ovarian cancer have thus far shown no strong
associations with disease. Doherty et al. [19] showed
a weak association with the variant alleles displaying
a protective role for the development of endometrial
cancer. Our results are in accordance with those since
the Met/Met genotype in this study appears to be
protective for endometrial cancer; however, in this study
the heterozygous genotype appears to be causative of
disease. Our results regarding CRC risk and V158M
are in accordance with the three previous studies
performed which showed no association; therefore we
conclude that it is highly unlikely that COMT affects
CRC risk in HNPCC patients [22-24].
Several limitations in our study warrant caution in
the interpretation of the findings presented. Firstly, the
size of the subgroups was in some cases quite small
and therefore lacked adequate power to detect a small
increase in cancer risk. Multiple comparisons were
performed to assess disease expression, mutation status
and mutation type, which increased the risk of type one
errors. Additionally, it is important for future studies to
look at the functions of the examined variants and their
associated genes to provide a clearer role of
susceptibility to disease. The assessment of such
interactions will be the focus of future analyses.
Although this study suggests that the heterozygous
genotype and homozygous mutant genotype are
causative and protective of endometrial/ovarian cancer
respectively, these associations should be carefully
interpreted and confirmed in a much larger population
of women that fit the clinical criteria for HNPCC and
have endometrial cancer in addition to a sporadic
endometrial cancer population.
In conclusion, the variation observed in MMR gene
mutation carriers in regards to disease expression,
mutation type, mutation status and age of diagnosis of
CRC in HNPCC families is not influenced by the COMT
V158M polymorphism. It appears that the polymorphism
might account for some of the endometrial/ovarian
cancer cases observed in the HNPCC MMR mutation
negative population and also in some patients confer
a protective role for developing endometrial/ovarian
cancer. It is likely that other modifying factors, both
genetic and environmental, play a role in the variation
in disease expression observed in HNPCC.
A Ac ck kn no ow wl le ed dg ge em me en nt ts s
This study was supported by funds from the NBN
Children’s Cancer Group and Hunter Medical
Research Institute (HMRI). 
R Re ef fe er re en nc ce es s
1. Watson P and Lynch HT. Cancer risk in mismatch repair gene
mutation carriers. Fam Cancer 2001; 1: 57-60.
2. Aaltonen LA, Salovaara R, Kristo P , Canzian F, Hemminki A,
Peltomaki P , Chadwick RB, Kaariainen H, Eskelinen M, Jarvinen
H, Mecklin JP and de la Chapelle A. Incidence of hereditary
nonpolyposis colorectal cancer and the feasibility of molecular
screening for the disease. N Engl J Med 1998; 338: 1481-1487.
3. Peltomaki P , Gao P and Mecklin JP . Genotype and phenotype
in hereditary nonpolyposis colon cancer: a study of families
with different vs. shared predisposing mutations. Fam
Cancer 2001; 1: 9-15.
4. Mitchell RJ, Farrington SM, Dunlop MG and Campbell H.
Mismatch repair genes hMLH1 and hMSH2 and colorectal
cancer: a HuGE review. Am J Epidemiol 2002; 156: 885-902.
5. Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H and van der
Zee AG. Gynecologic screening in hereditary nonpolyposis
colorectal cancer. Gynecol Oncol 2003; 91: 74-80.
6. Zhu BT and Conney AH. Is 2-methoxyestradiol an endogenous
estrogen metabolite that inhibits mammary carcinogenesis?
Cancer Res 1998; 58: 2269-2277. 
7. Cavalieri E, Frenkel K, Liehr JG, Rogan E and Roy D. Estrogens
as endogenous genotoxic agents – DNA adducts and mutations.
J Natl Cancer Inst Monogr 2000; (27): 75-93.
8. Yager JD and Liehr JG. Molecular mechanisms of estrogen
carcinogenesis. Annu Rev Pharmacol Toxicol 1996; 36: 203-232. 
9. Dawling S, Roodi N, Mernaugh RL, Wang X and Parl FF.
Catechol-O-methyltransferase (COMT)-mediated metabolism
of catechol estrogens: comparison of wild-type and variant
COMT isoforms. Cancer Res 2001; 61: 6716-6722.
10. Service RF. New role for estrogen in cancer? Science 1998;
279: 1631-1633. Erratum in: Science 1998; 280: 2033.
11. Inoue H, Shibuta K, Matsuyama A, Yoshinaga K, Sadanaga N,
Ueo H, Barnard GF and Mori M. Genetic susceptibility of
catechol-O-methyltransferase polymorphism in Japanese
patients with breast cancer. Oncol Rep 2005; 14: 707-712.
12.  Weinshilboum RM and Raymond FA. Inheritance of low
erythrocyte catechol-o-methyltransferase activity in man. Am J
Hum Genet 1977; 29: 125-135.
13.  Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K,
Julkunen I and Taskinen J. Kinetics of human soluble and
membrane-bound catechol O-methyltransferase: a revised
The Association of the COMT V158M Polymorphism with Endometrial/Ovarian Cancer in HNPCC Families Adhering to the Amsterdam Criteria H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2006; 4(2) 102
mechanism and description of the thermolabile variant of the
enzyme. Biochemistry 1995; 34: 4202-4210.
14. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL and
Weinshilboum RM. Human catechol-O-methyltransferase
pharmacogenetics: description of a functional polymorphism
and its potential application to neuropsychiatric disorders.
Pharmacogenetics 1996; 6: 243-250.
15. Nock NL, Cicek MS, Li L, Liu X, Rybicki BA, Moreira A, Plummer
SJ, Casey G and Witte JS. Polymorphisms in estrogen
bioactivation, detoxification and oxidative DNA base excision
repair genes and prostate cancer risk. Carcinogenesis 2006;
[epub ahead of print].
16. Lin WY, Chou YC, Wu MH, Jeng YL, Huang HB, You SL, Chu TY,
Chen CJ and Sun CA. Polymorphic catechol-O-methyltransferase
gene, duration of estrogen exposure, and breast cancer risk:
a nested case-control study in Taiwan. Cancer Detect
Prev 2005; 29: 427-432. Epub 2005 Sep 26.
17. Garner EI, Stokes EE, Berkowitz RS, Mok SC and Cramer DW.
Polymorphisms of the estrogen-metabolizing genes CYP17 and
catechol-O-methyltransferase and risk of epithelial ovarian
cancer. Cancer Res 2002; 62: 3058-3062.
18. Sellers TA, Schildkraut JM, Pankratz VS, Vierkant RA, Fredericksen
ZS, Olson JE, Cunningham J, Taylor W, Liebow M, McPherson C,
Hartmann LC, Pal T and Adjei AA. Estrogen bioactivation,
genetic polymorphisms, and ovarian cancer. Cancer Epidemiol
Biomarkers Prev 2005; 14 (11 Pt 1): 2536-2543.
19. Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ,
Houck JR, Voigt LF, Rossing MA, Schwartz SM and Chen C.
Genetic factors in catechol estrogen metabolism in relation to
the risk of endometrial cancer. Cancer Epidemiol Biomarkers
Prev 2005; 14: 357-366.
20. McGrath M, Hankinson SE, Arbeitman L, Colditz GA, Hunter DJ
and De Vivo I. Cytochrome P450 1B1 and catechol-O-methyl-
transferase polymorphisms and endometrial cancer susceptibility.
Carcinogenesis 2004; 25: 559-565. Epub 2003 Dec 4.
21. Sasaki M, Kaneuchi M, Sakuragi N and Dahiya R. Multiple
promoters of catechol-O-methyltransferase gene are selectively
inactivated by CpG hypermethylation in endometrial cancer.
Cancer Res 2003; 63: 3101-3106.
22. Huber A, Bentz EK, Schneeberger C, Huber JC, Hefler L and
Tempfer C. Ten polymorphisms of estrogen-metabolizing genes
and a family history of colon cancer – an association study of
multiple gene-gene interactions. J Soc Gynecol Investig 2005;
12: e51-54.
23. Mas S, Laso N, Lafuente MJ, Lafuente A, Molina R, Ballesta A,
Zheng S and Wiencke JK. Cancer, genes, and catechol estrogen
metabolites. Int J Clin Oncol 2003; 8: 65-66.
24. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A,
Guino E, Navarro M, de Oca J, Capella G, Canzian F and Bellvitge
Colorectal Cancer Study Group. A comprehensive analysis of
phase I and phase II metabolism gene polymorphisms and risk of
colorectal cancer. Pharmacogenet Genomics 2005; 15: 535-546.
25. Miller SA, Dykes DD and Polesky HF. A simple salting out
procedure for extracting DNA from human nucleated cells.
Nucleic Acids Res 1988; 16: 1215.
26. Li Y, Yang X, van Breemen RB and Bolton JL. Characterization
of two new variants of human catechol O-methyltransferase in
vitro. Cancer Lett 2005; 230: 81-89.
27. Hoda F, Nicholl D, Bennett P , Arranz M, Aitchison KJ, al-Chalabi
A, Kunugi H, Vallada H, Leigh PN, Chaudhuri KR and Collier
DA. No association between Parkinson’s disease and low-activity
alleles of catechol O-methyltransferase. Biochem Biophys Res
Commun 1996; 228: 780-784.
28. Denschlag D, Bentz EK, Hefler L, Pietrowski D, Zeillinger R,
Tempfer C and Tong D. Genotype distribution of estrogen
receptor-alpha, catechol-O-methyltransferase, and cytochrome
P450 17 gene polymorphisms in Caucasian women with uterine
leiomyomas. Fertil Steril 2006; 85: 462-467.
29. Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR,
Stone KL, Morin PA, Greene D and Cauley JA. Estrogen
metabolizing polymorphisms and breast cancer risk among older
white women. Breast Cancer Res Treat 2005; 93: 261-270.
30. Comings DE and MacMurray JP . Molecular heterosis: a review.
Mol Genet Metab 2000; 71: 19-31. 
Katie A. Ashton, Cliff J. Meldrum, Mary L. McPhillips, Janina Suchy, Grzegorz Kurzawski, Jan Lubinski, Rodney J. Scott